XtalPi Partners with Janssen to Accelerate Drug Discovery
China-based XtalPi, Inc. has announced a research collaboration with Janssen Pharmaceutica NV, one of the...
NMPA Approves Kyowa Hakko Kirin’s Mogamulizumab for Sezary Syndrome and Mycosis Fungoides
Kyowa Hakko Kirin China Pharmaceutical Co., Ltd’s mogamulizumab, a first-in-class chemokine receptor type 4 (CCR4)...
NMPA Grants Second Approval to Henlius’ Serplulimab for Lung Cancer
The National Medical Products Administration (NMPA) has granted a second marketing approval to HaiSiZhuang (serplulimab),...
Innovent’s CLDN18.2 ADC IBI343 Begins Phase I Trial in Australia
Innovent Biologics Inc. (HKG: 1801) has announced the first subject dosing in a Phase I...
Ascletis Signs Pact with Pfizer China for Ritonavir Tablets
Ascletis Pharma Inc. (HKG: 1672) announced that its wholly-owned subsidiary Ascletis Pharmaceuticals Co., Ltd has...
Eli Lilly Cancels Licensing Deal for Fosun Pharma’s FCN-338
Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its US partner...
Junshi Biosciences Reports 55% Drop in Q3 Revenues
Shanghai-based biotech Junshi Biosciences (HKG: 1877) released its financial report for the third quarter of...
Shanghai Duoning Bio Partners with Lisure for Disposable Biopharma System
China’s Shanghai Duoning Biotechnology Co., Ltd has entered into a partnership with compatriot firm Lisure...
Santhera and ReveraGen Submit NDA for Vamorolone in Duchenne Muscular Dystrophy
Swiss firm Santhera Pharmaceuticals and US-based ReveraGen BioPharma, Inc have announced the rolling submission of...
Ortho-K Lenses Included in Hebei’s Volume-Based Procurement List
The drug and medical device procurement center of Hebei Province released a notification regarding the...
Innovent’s Tyvyt Approved for New Gastric Cancer Indication by NMPA
China-based Innovent Biologics, Inc. (HKG: 1801) and its partner Eli Lilly & Co. (NYSE: LLY)...
Zhejiang Huahai Receives FDA ANDA Approval for Generic Tecfidera
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received Abbreviated New...
Novartis Expands Strategic Collaboration with Bo’Ao Lecheng Pilot Zone
Novartis (NYSE: NVS) announced a further strategic collaboration with the Bo’Ao Lecheng Medical Tourism Pilot...
Salubris Partners with Alpha Molecular for AI-Driven Obesity Drug Development
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has entered into a partnership with compatriot...
RemeGen Reports 397.47% YOY Revenue Growth in Q3 2022
China-based pharma firm RemeGen (HKG: 9995) released its Q3 2022 financial report, showing significant growth...
Innovent’s Parsaclisib Filed for Marketing Approval in China
China’s Center for Drug Evaluation (CDE) has received a marketing approval application for Innovent Biologics...
Proheal Pharmaceuticals Initiates Clinical Study for PHP1003 in Thyroid-Associated Ophthalmopathy
Proheal Pharmaceuticals, a Suzhou-based developer of drugs for ophthalmology and autoimmune diseases, announced the first...
HutchMed Initiates Phase II/III Study for Elunate and Tyvyt in Renal Cell Carcinoma
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase...
Shanghai Pharmaceuticals Reports 12.86% YOY Revenue Growth in Q3 2022
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) released its Q3 2022 financial report, recording RMB 62.904...
Recbio’s Neoadjuvant HPV Vaccine Accepted for Review by NMPA
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced that a clinical trial...